Woei-A-Jin F, Zheng S, Kilicsoy I, Hudig F, Luelmo S, Kroep J
Oncologist. 2020; 25(2):e341-e350.
PMID: 32043782
PMC: 7011667.
DOI: 10.1634/theoncologist.2019-0222.
Murray C, De Gelder T, Pringle N, Johnson J, Doherty M
Can Oncol Nurs J. 2019; 26(1):29-39.
PMID: 31148744
PMC: 6516315.
DOI: 10.5737/236880762612939.
Murray C, De Gelder T, Pringle N, Johnson J, Doherty M
Can Oncol Nurs J. 2019; 26(1):19-28.
PMID: 31148725
PMC: 6516318.
DOI: 10.5737/236880762611928.
Pileggi C, Di Sanzo M, Mascaro V, Marafioti M, Costanzo F, Pavia M
PLoS One. 2017; 12(6):e0179016.
PMID: 28622367
PMC: 5473533.
DOI: 10.1371/journal.pone.0179016.
Manduzio P
Clin Case Rep. 2015; 3(6):361-7.
PMID: 26185629
PMC: 4498843.
DOI: 10.1002/ccr3.262.
A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.
Sanford D, Hsia C
Curr Oncol. 2015; 22(2):e128-32.
PMID: 25908918
PMC: 4399621.
DOI: 10.3747/co.22.2100.
Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.
Ko B, Chang C, Chang M, Chen T, Chiou T, Chiu C
Int J Hematol. 2014; 100(1):7-15.
PMID: 24924953
DOI: 10.1007/s12185-014-1607-x.
Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia.
Gao C, Li L, Chen B, Song H, Cheng J, Zhang X
Patient Prefer Adherence. 2014; 8:513-7.
PMID: 24790419
PMC: 4003266.
DOI: 10.2147/PPA.S56238.
Iron chelation therapy in myelodysplastic syndromes: where do we stand?.
Mitchell M, Gore S, Zeidan A
Expert Rev Hematol. 2013; 6(4):397-410.
PMID: 23991926
PMC: 4124619.
DOI: 10.1586/17474086.2013.814456.
Guidelines on haemovigilance of post-transfusional iron overload.
Remacha A, Sanz C, Contreras E, Diaz de Heredia C, Grifols J, Lozano M
Blood Transfus. 2012; 11(1):128-39.
PMID: 22790272
PMC: 3557483.
DOI: 10.2450/2012.0114-11.
An update on iron chelation therapy.
Poggiali E, Cassinerio E, Zanaboni L, Cappellini M
Blood Transfus. 2012; 10(4):411-22.
PMID: 22790257
PMC: 3496216.
DOI: 10.2450/2012.0008-12.
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
Gattermann N, Finelli C, Porta M, Fenaux P, Stadler M, Guerci-Bresler A
Haematologica. 2012; 97(9):1364-71.
PMID: 22419577
PMC: 3436237.
DOI: 10.3324/haematol.2011.048546.
Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome.
Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y
Int J Hematol. 2012; 95(5):527-34.
PMID: 22407873
DOI: 10.1007/s12185-012-1048-3.
A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS.
Giagounidis A, di Priolo S, Ille S, Fenaux P
Ann Hematol. 2011; 90(6):667-73.
PMID: 21327403
PMC: 3087870.
DOI: 10.1007/s00277-011-1181-8.
Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch H
Drugs. 2011; 71(2):155-77.
PMID: 21275444
DOI: 10.2165/11585280-000000000-00000.
Iron overload in patients undergoing hematopoietic stem cell transplantation.
Pullarkat V
Adv Hematol. 2010; 2010.
PMID: 20871852
PMC: 2943091.
DOI: 10.1155/2010/345756.
Iron chelation therapy in myelodysplastic syndromes.
Messa E, Cilloni D, Saglio G
Adv Hematol. 2010; 2010:756289.
PMID: 20672005
PMC: 2905902.
DOI: 10.1155/2010/756289.